TVG Streptococcus suis success underpins vaccine delivery platform potential
TVG Streptococcus suis success underpins vaccine delivery platform potential
TVG is delighted to announce that a vaccine candidate to tackle Streptococcus suis (“S.suis”) in pigs developed using grant funding from Innovate UK funding has outperformed a leading commercially available vaccine in a challenge trial conducted at Moredun Scientific Limited (“MSL”).
The trial showed TVG’s vaccine is effective against a heterologous serotype of the disease. A challenge model with S. suis serotype 1 in young pigs was developed by MSL specifically for this programme. Our vaccine demonstrated solid clinical protection based upon several parameters. The candidate vaccine was designed to incorporate antigens broadly present in most S. suis serotypes, with the specific intention of creating a cross-serotype protective vaccine. This is a market gap with the currently available commercial vaccines for S. suis.